Cargando…

The longitudinal relationship between fatigue, depression, anxiety, disability, and adherence with cognitive status in patients with early multiple sclerosis treated with interferon beta-1a

BACKGROUND: Cognitive dysfunction is common in multiple sclerosis and may worsen with reduced treatment adherence. We examined longitudinal relationships between anxiety, depression, fatigue, disability and adherence with cognitive status in patients with relapsing-remitting multiple sclerosis (MS)...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Ballegooijen, Hanne, van der Hiele, Karin, Enzinger, Christian, de Voer, Gert, Visser, Leo H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207145/ https://www.ncbi.nlm.nih.gov/pubmed/35733640 http://dx.doi.org/10.1016/j.ensci.2022.100409

Ejemplares similares

Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment
por: Visser, Leo H, et al.
Publicado: (2016)

Work Participation and Executive Abilities in Patients with Relapsing-Remitting Multiple Sclerosis
por: van der Hiele, Karin, et al.
Publicado: (2015)

Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart(®) injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis
por: Krol, Marieke, et al.
Publicado: (2017)

Reliability and Responsiveness of Cardiopulmonary Exercise Testing in Fatigued Persons with Multiple Sclerosis and Low to Mild Disability
por: Heine, Martin, et al.
Publicado: (2015)

A Pilot Study on Factors Involved with Work Participation in the Early Stages of Multiple Sclerosis
por: Van der Hiele, Karin, et al.
Publicado: (2014)

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis
por: Manceau, Philippe, et al.
Publicado: (2014)

Impairment, disability and fatigue in multiple sclerosis
por: Shahrbanian, Shahnaz, et al.
Publicado: (2018)

Work difficulties in people with multiple sclerosis: The role of anxiety, depression and coping
por: van Egmond, EEA, et al.
Publicado: (2022)

The Impact of Motor Disability and the Level of Fatigue on Adherence to Therapeutic Recommendations in Patients with Multiple Sclerosis Treated with Immunomodulation
por: Ślusarz, Robert, et al.
Publicado: (2021)

Self-reported ongoing adherence to diet is associated with lower depression, fatigue, and disability, in people with multiple sclerosis
por: Yu, Maggie, et al.
Publicado: (2023)

MxA mRNA Quantification and Disability Progression in Interferon Beta-Treated Multiple Sclerosis Patients
por: Serana, Federico, et al.
Publicado: (2014)

Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart(®) in patients with multiple sclerosis
por: Edo Solsona, María Dolores, et al.
Publicado: (2017)

Beta‐interferon exposure and onset of secondary progressive multiple sclerosis
por: Zhang, T., et al.
Publicado: (2015)

Disability and Fatigue Can Be Objectively Measured in Multiple Sclerosis
por: Motta, Caterina, et al.
Publicado: (2016)

‘Beta-interferons’ and ‘oligoclonal bands’ in multiple sclerosis in India
por: Hassan, K. M.
Publicado: (2011)

Anxiety in Multiple Sclerosis Patients: A Preliminary Examination of the Effect of Fatigue, Physical Disability, and Low Self-Compassionate Attitude
por: Carvalho, T., et al.
Publicado: (2022)

Poststroke Fatigue: Who Is at Risk for an Increase in Fatigue?
por: van Eijsden, Hanna Maria, et al.
Publicado: (2012)

Participatory Workshops are Not Enough to Prevent Policy Implementation Failures: An Example of a Policy Development Process Concerning the Drug Interferon-beta for Multiple Sclerosis
por: Moret-Hartman, Margriet, et al.
Publicado: (2007)

Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry
por: Hellwig, Kerstin, et al.
Publicado: (2020)

Multiple Sclerosis in Older Adults: The Clinical Profile and Impact of Interferon Beta Treatment
por: Shirani, Afsaneh, et al.
Publicado: (2015)

Response to Interferon-Beta Treatment in Afro-Caribbeans with Multiple Sclerosis
por: Jeannin, S., et al.
Publicado: (2011)

Thrombotic Microangiopathy in Interferon‐beta‐Treated Multiple Sclerosis Patient
por: Malekzadeh, Masoud Mohammad, et al.
Publicado: (2020)

Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer
por: Blaauboer, Amber, et al.
Publicado: (2020)

The impact of disability, fatigue and sleep quality on the quality of life in multiple sclerosis
por: Ghaem, Haleh, et al.
Publicado: (2008)

Fatigue, Depression, and Anxiety Among Ambulating Multiple Sclerosis Patients
por: AlSaeed, Safanah, et al.
Publicado: (2022)

Deficient Phosphorylation of Stat1 in Leukocytes Identifies Neutralizing Antibodies in Multiple Sclerosis Patients Treated with Interferon-Beta
por: Gavasso, Sonia, et al.
Publicado: (2014)

The MS@Work study: a 3-year prospective observational study on factors involved with work participation in patients with relapsing-remitting Multiple Sclerosis
por: van der Hiele, Karin, et al.
Publicado: (2015)

Influence of Interferon beta treatment on quality of life in multiple sclerosis patients
por: Simone, Isabella Laura, et al.
Publicado: (2006)

Beta-interferons in multiple sclerosis: A single center experience in India
por: Gupta, Salil, et al.
Publicado: (2010)

Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis
por: Marziniak, Martin, et al.
Publicado: (2014)

Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
por: Castrop, Florian, et al.
Publicado: (2013)

PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update
por: Reuss, Reinhard
Publicado: (2013)

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
por: Cocco, Eleonora, et al.
Publicado: (2015)

Neutralizing Antibodies Against Interferon-Beta in Korean Patients with Multiple Sclerosis
por: Hyun, Jae-Won, et al.
Publicado: (2018)

Thrombotic microangiopathy associated with interferon-beta treatment in patients with multiple sclerosis
por: Baghbanian, Seyed Mohammad, et al.
Publicado: (2018)

The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis
por: Madsen, Claus
Publicado: (2017)

Interferon-Beta-Induced Headache in Patients with Multiple Sclerosis: Frequency and Characterization
por: Elmazny, Alaa, et al.
Publicado: (2020)

Depression and anxiety in patients with multiple sclerosis treated with interferon-beta or fingolimod: Role of indoleamine 2,3-dioxygenase and pro-inflammatory cytokines
por: Tauil, Carlos B., et al.
Publicado: (2020)

How is neuromuscular fatigability affected by perceived fatigue and disability in people with multiple sclerosis?
por: Royer, Nicolas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mnu1boj17h4pv3hbger6ep646c